Ascletis Advances Oral Amylin Agonist ASC39, Mimicking Eli Lilly's Approach
Event summary
- Ascletis Pharma has selected ASC39, a novel oral small molecule amylin receptor agonist, as its clinical development candidate for obesity treatment.
- Preclinical data indicate ASC39 demonstrates comparable selectivity and efficacy to eloralintide, with similar EC50 values for hAMY1R and comparable weight loss in DIO rat models.
- Ascletis plans to submit an Investigational New Drug (IND) application for ASC39 oral tablets to the U.S. FDA in Q3 2026.
- ASC39 was developed using Ascletis’ AI-assisted Structure-Based Drug Discovery (AISBDD) technology.
The big picture
Ascletis is pursuing a strategy of oral amylin receptor agonists, mirroring Eli Lilly’s approach with eloralintide, to address the growing market for obesity treatments. The company’s use of AI-driven drug discovery suggests a focus on efficiency and potentially novel chemical scaffolds. The success of ASC39 will hinge on demonstrating a compelling clinical profile and navigating a crowded therapeutic space.
What we're watching
- Regulatory Risk
- The FDA’s review of Ascletis’ IND submission for ASC39 will be critical, and any delays or requests for additional data could impact the program's timeline and cost.
- Clinical Efficacy
- While preclinical data are promising, the true test will be ASC39’s efficacy and safety in human clinical trials, which will determine its potential to compete with existing and emerging obesity treatments.
- Commercialization
- Ascletis’ ability to successfully commercialize ASC39, particularly given the competitive landscape in obesity treatment, will depend on demonstrating a clear advantage over existing therapies and securing favorable reimbursement.
Related topics